Vernalis plc (VER) Rating Reiterated by RX Securities

Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by stock analysts at RX Securities in a research report issued to clients and investors on Monday, August 7th.

A number of other research analysts also recently issued reports on VER. N+1 Singer reaffirmed a “hold” rating and set a GBX 28 ($0.36) price target on shares of Vernalis plc in a report on Monday, August 7th. Stifel Nicolaus lowered their price target on Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.31) and set a “hold” rating on the stock in a report on Friday, April 21st. Numis Securities Ltd reaffirmed an “add” rating and set a GBX 29 ($0.38) price target on shares of Vernalis plc in a report on Friday, April 21st. Finally, Panmure Gordon downgraded Vernalis plc to a “hold” rating and set a GBX 65 ($0.84) price target on the stock. in a report on Friday, April 21st. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 39.40 ($0.51).

Shares of Vernalis plc (VER) opened at 17.00 on Monday. The stock’s 50 day moving average price is GBX 17.74 and its 200 day moving average price is GBX 21.54. The stock’s market capitalization is GBX 89.48 million. Vernalis plc has a 12 month low of GBX 15.25 and a 12 month high of GBX 45.75.

ILLEGAL ACTIVITY WARNING: “Vernalis plc (VER) Rating Reiterated by RX Securities” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/08/19/vernalis-plc-ver-rating-reiterated-by-rx-securities-updated.html.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

What are top analysts saying about Vernalis plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vernalis plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit